FGEN
Fibrogen
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 1
consensus rating "Strong Buy"
Revenue Beats Expectation
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About FGEN
Fibrogen, Inc.
A biopharmaceutical company that developing novel therapeutic agents to treat anemia, fibrotic disease, and cancer
Biological Technology
Invalid Date
11/14/2014
NASDAQ Stock Exchange
225
12-31
Common stock
350 Bay Street, Suite 100 #6009, San Francisco, CA 94133
--
Fibrogen, Inc., was incorporated in Delaware in 1993. The company is a biopharmaceutical company focused on the development of new therapies in the frontiers of cancer biology and anemia. The company is developing FG-3246, a potential first-in-class antibody-drug conjugate targeting CD46 for the treatment of metastatic castration-resistant prostate cancer and potentially other cancers. The program also includes the development of FG-3180, a related CD46 targeted positron emission tomography biomarker and imaging agent.
Company Financials
EPS
FGEN has released its 2024 Q4 earnings. EPS was reported at 0.18, versus the expected -0.20, beating expectations. The chart below visualizes how FGEN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
FGEN has released its 2024 Q3 earnings report, with revenue of 46.33M, reflecting a YoY change of 15.45%, and net profit of -17.08M, showing a YoY change of 73.14%. The Sankey diagram below clearly presents FGEN’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
